Dexamethasone intravitreal implant in serpiginous choroiditis

Elisabetta Miserocchi, L Berchicci, L Iuliano, G Modorati, F Bandello

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background/aims To assess the efficacy and safety of dexamethasone (DEX) intravitreal implant in patients with active serpiginous choroiditis (SC) already receiving maximal tolerated systemic immunosuppressive therapy. Methods In this retrospective longitudinal study we evaluated patients receiving 0.7 mg DEX intravitreal implant for active SC despite maximal systemic immunosuppression. Medical history was reviewed over a period of 18 months for each patient. We diagnosed SC activity using direct fundus examination and blue-light fundus autofluorescence. Primary outcomes were the rate of disease control and functional changes at end of follow-up. Secondary outcomes were the incidence of injection-related adverse events and the success of immunosuppression tapering at the last examination. Results We examined eight eyes of seven patients. We controlled SC activity with one injection in five eyes, two injections in one eye, and three injections in two eyes (total of 13 implants). Best-corrected visual acuity at the end of the investigational period improved in two eyes (25%), remained stable in four eyes (50%) and decreased in two eyes (25%). Three eyes showed transient intraocular pressure increase and two eyes disclosed cataract progression. The average dosage of systemic prednisone at baseline and after DEX intravitreal implant decreased from 8.8 to 2.8 mg/day. Conclusions Dexamethasone intravitreal implant may be an effective treatment option to control active serpiginous lesions in patients in whom increased systemic corticosteroid therapy is contraindicated. © 2016 by the BMJ Publishing Group Ltd.
Original languageEnglish
Pages (from-to)327-332
Number of pages6
JournalBritish Journal of Ophthalmology
Volume101
Issue number3
DOIs
Publication statusPublished - 2017

Fingerprint

Choroiditis
Dexamethasone
Injections
Immunosuppression
Immunosuppressive Agents
Prednisone
Intraocular Pressure
Cataract
Visual Acuity
Longitudinal Studies
Adrenal Cortex Hormones
Therapeutics
Retrospective Studies

Cite this

Dexamethasone intravitreal implant in serpiginous choroiditis. / Miserocchi, Elisabetta; Berchicci, L; Iuliano, L; Modorati, G; Bandello, F.

In: British Journal of Ophthalmology, Vol. 101, No. 3, 2017, p. 327-332.

Research output: Contribution to journalArticle

Miserocchi, Elisabetta ; Berchicci, L ; Iuliano, L ; Modorati, G ; Bandello, F. / Dexamethasone intravitreal implant in serpiginous choroiditis. In: British Journal of Ophthalmology. 2017 ; Vol. 101, No. 3. pp. 327-332.
@article{71653f135ce24b2683c3867818ed00bd,
title = "Dexamethasone intravitreal implant in serpiginous choroiditis",
abstract = "Background/aims To assess the efficacy and safety of dexamethasone (DEX) intravitreal implant in patients with active serpiginous choroiditis (SC) already receiving maximal tolerated systemic immunosuppressive therapy. Methods In this retrospective longitudinal study we evaluated patients receiving 0.7 mg DEX intravitreal implant for active SC despite maximal systemic immunosuppression. Medical history was reviewed over a period of 18 months for each patient. We diagnosed SC activity using direct fundus examination and blue-light fundus autofluorescence. Primary outcomes were the rate of disease control and functional changes at end of follow-up. Secondary outcomes were the incidence of injection-related adverse events and the success of immunosuppression tapering at the last examination. Results We examined eight eyes of seven patients. We controlled SC activity with one injection in five eyes, two injections in one eye, and three injections in two eyes (total of 13 implants). Best-corrected visual acuity at the end of the investigational period improved in two eyes (25{\%}), remained stable in four eyes (50{\%}) and decreased in two eyes (25{\%}). Three eyes showed transient intraocular pressure increase and two eyes disclosed cataract progression. The average dosage of systemic prednisone at baseline and after DEX intravitreal implant decreased from 8.8 to 2.8 mg/day. Conclusions Dexamethasone intravitreal implant may be an effective treatment option to control active serpiginous lesions in patients in whom increased systemic corticosteroid therapy is contraindicated. {\circledC} 2016 by the BMJ Publishing Group Ltd.",
author = "Elisabetta Miserocchi and L Berchicci and L Iuliano and G Modorati and F Bandello",
year = "2017",
doi = "10.1136/bjophthalmol-2015-307820",
language = "English",
volume = "101",
pages = "327--332",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "3",

}

TY - JOUR

T1 - Dexamethasone intravitreal implant in serpiginous choroiditis

AU - Miserocchi, Elisabetta

AU - Berchicci, L

AU - Iuliano, L

AU - Modorati, G

AU - Bandello, F

PY - 2017

Y1 - 2017

N2 - Background/aims To assess the efficacy and safety of dexamethasone (DEX) intravitreal implant in patients with active serpiginous choroiditis (SC) already receiving maximal tolerated systemic immunosuppressive therapy. Methods In this retrospective longitudinal study we evaluated patients receiving 0.7 mg DEX intravitreal implant for active SC despite maximal systemic immunosuppression. Medical history was reviewed over a period of 18 months for each patient. We diagnosed SC activity using direct fundus examination and blue-light fundus autofluorescence. Primary outcomes were the rate of disease control and functional changes at end of follow-up. Secondary outcomes were the incidence of injection-related adverse events and the success of immunosuppression tapering at the last examination. Results We examined eight eyes of seven patients. We controlled SC activity with one injection in five eyes, two injections in one eye, and three injections in two eyes (total of 13 implants). Best-corrected visual acuity at the end of the investigational period improved in two eyes (25%), remained stable in four eyes (50%) and decreased in two eyes (25%). Three eyes showed transient intraocular pressure increase and two eyes disclosed cataract progression. The average dosage of systemic prednisone at baseline and after DEX intravitreal implant decreased from 8.8 to 2.8 mg/day. Conclusions Dexamethasone intravitreal implant may be an effective treatment option to control active serpiginous lesions in patients in whom increased systemic corticosteroid therapy is contraindicated. © 2016 by the BMJ Publishing Group Ltd.

AB - Background/aims To assess the efficacy and safety of dexamethasone (DEX) intravitreal implant in patients with active serpiginous choroiditis (SC) already receiving maximal tolerated systemic immunosuppressive therapy. Methods In this retrospective longitudinal study we evaluated patients receiving 0.7 mg DEX intravitreal implant for active SC despite maximal systemic immunosuppression. Medical history was reviewed over a period of 18 months for each patient. We diagnosed SC activity using direct fundus examination and blue-light fundus autofluorescence. Primary outcomes were the rate of disease control and functional changes at end of follow-up. Secondary outcomes were the incidence of injection-related adverse events and the success of immunosuppression tapering at the last examination. Results We examined eight eyes of seven patients. We controlled SC activity with one injection in five eyes, two injections in one eye, and three injections in two eyes (total of 13 implants). Best-corrected visual acuity at the end of the investigational period improved in two eyes (25%), remained stable in four eyes (50%) and decreased in two eyes (25%). Three eyes showed transient intraocular pressure increase and two eyes disclosed cataract progression. The average dosage of systemic prednisone at baseline and after DEX intravitreal implant decreased from 8.8 to 2.8 mg/day. Conclusions Dexamethasone intravitreal implant may be an effective treatment option to control active serpiginous lesions in patients in whom increased systemic corticosteroid therapy is contraindicated. © 2016 by the BMJ Publishing Group Ltd.

U2 - 10.1136/bjophthalmol-2015-307820

DO - 10.1136/bjophthalmol-2015-307820

M3 - Article

VL - 101

SP - 327

EP - 332

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 3

ER -